PDE5 is Converted to an Activated State Upon CGMP Binding to the GAF A Domain

Overview

Journal EMBO J

Specialties Biotechnology
Molecular Biology

Date 2003 Jan 30

PMID 12554648

Citations 69

Authors

Sergei D Rybalkin

Irina G Rybalkina

Masami Shimizu-Albergine

Xiao-Bo Tang

Joseph A Beavo

Affiliations

Soon will be listed here.

Abstract

cGMP-specific, cGMP-binding phosphodiesterase (PDE5) regulates such physiological processes as smooth muscle relaxation and neuronal survival. PDE5 contains two N-terminal domains (GAF A and GAF B), but the functional roles of these domains have not been determined. Here we show that recombinant PDE5 is activated directly upon cGMP binding to the GAF A domain, and this effect does not require PDE5 phosphorylation. PDE5 exhibited time- and concentration-dependent reversible activation in response to cGMP, with the highest activation (9- to 11-fold) observed at low substrate concentrations (0.1 micro M cGMP). A monoclonal antibody directed against GAF A blocked cGMP binding, prevented PDE5 activation and decreased basal activity, revealing that PDE5 in its non-activated state has low intrinsic catalytic activity. Activated PDE5 showed higher sensitivity towards sildenafil than non-activated PDE5. The stimulatory effect of cGMP binding on the catalytic activity of PDE5 suggests that this mechanism of enzyme activation may be common among other GAF domain-containing proteins. The data also suggest that development of agonists and antagonists of PDE5 activity based on binding to this site might be possible.

Citing Articles

Cone photoreceptor phosphodiesterase PDE6H inhibition regulates cancer cell growth and metabolism, replicating the dark retina response.

Yalaz C, Bridges E, Alham N, Zois C, Chen J, Bensaad K Cancer Metab. 2024; 12(1):5.

PMID: 38350962 PMC: 10863171. DOI: 10.1186/s40170-023-00326-y.

Phosphodiesterase in heart and vessels: from physiology to diseases.

Fu Q, Wang Y, Yan C, Xiang Y Physiol Rev. 2023; 104(2):765-834.

PMID: 37971403 PMC: 11281825. DOI: 10.1152/physrev.00015.2023.

Coupling of conformational dynamics and inhibitor binding in the phosphodiesterase-5 family.

Tripathi S, Cote R, Vashisth H Protein Sci. 2023; 32(8):e4720.

PMID: 37407431 PMC: 10367598. DOI: 10.1002/pro.4720.

PDE5 inhibitors and gastric mucosa: implications for the management of peptic ulcer disease.

Turki Jalil A, Hassan M, Ziyad R, Jasim I, Zabibah R, Fadhil A Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(10):2261-2267.

PMID: 37119288 DOI: 10.1007/s00210-023-02503-8.

Intracellular cGMP increase is not involved in thyroid cancer cell death.

Alessandro S, Paradiso E, Lazzaretti C, Sperduti S, Perri C, Antoniani F PLoS One. 2023; 18(3):e0283888.

PMID: 36996255 PMC: 10062617. DOI: 10.1371/journal.pone.0283888.

References

Corbin J, Turko I, Beasley A, Francis S . Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem. 2000; 267(9):2760-7. DOI: 10.1046/j.1432-1327.2000.01297.x. View

Anantharaman V, Koonin E, Aravind L . Regulatory potential, phyletic distribution and evolution of ancient, intracellular small-molecule-binding domains. J Mol Biol. 2001; 307(5):1271-92. DOI: 10.1006/jmbi.2001.4508. View

Mullershausen F, Russwurm M, Thompson W, Liu L, Koesling D, Friebe A . Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol. 2001; 155(2):271-8. PMC: 2198829. DOI: 10.1083/jcb.200107001. View

Aravind L, Ponting C . The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci. 1998; 22(12):458-9. DOI: 10.1016/s0968-0004(97)01148-1. View

Wyatt T, Naftilan A, Francis S, Corbin J . ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol. 1998; 274(2):H448-55. DOI: 10.1152/ajpheart.1998.274.2.H448. View

Sonnenburg W, Rybalkin S, Bornfeldt K, KWAK K, Rybalkina I, Beavo J . Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. Methods. 1998; 14(1):3-19. DOI: 10.1006/meth.1997.0561. View

Ballard S, Gingell C, Tang K, Turner L, Price M, Naylor A . Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998; 159(6):2164-71. DOI: 10.1016/S0022-5347(01)63299-3. View

Rybalkin S, Rybalkina I, Feil R, Hofmann F, Beavo J . Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem. 2001; 277(5):3310-7. DOI: 10.1074/jbc.M106562200. View

Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A . The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2002; 13(5):282-90. DOI: 10.1038/sj.ijir.3900726. View

10.

Eardley I, Cartledge J . Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract. 2002; 56(4):300-4. View

11.

Kanacher T, Schultz A, Linder J, Schultz J . A GAF-domain-regulated adenylyl cyclase from Anabaena is a self-activating cAMP switch. EMBO J. 2002; 21(14):3672-80. PMC: 126120. DOI: 10.1093/emboj/cdf375. View

12.

Okada D, Asakawa S . Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP. Biochemistry. 2002; 41(30):9672-9. DOI: 10.1021/bi025727+. View

13.

Yamazaki A, Sen I, Bitensky M, Casnellie J, Greengard P . Cyclic GMP-specific, high affinity, noncatalytic binding sites on light-activated phosphodiesterase. J Biol Chem. 1980; 255(23):11619-24. View

14.

Martins T, Mumby M, Beavo J . Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem. 1982; 257(4):1973-9. View

15.

Thomas M, Francis S, Corbin J . Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem. 1990; 265(25):14964-70. View

16.

Thomas M, Francis S, Corbin J . Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem. 1990; 265(25):14971-8. View

17.

Stroop S, Beavo J . Sequence homology and structure--function studies of the bovine cyclic-GMP-stimulated and retinal phosphodiesterases. Adv Second Messenger Phosphoprotein Res. 1992; 25:55-71. View

18.

McAllister-Lucas L, Sonnenburg W, Kadlecek A, Seger D, Trong H, Colbran J . The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem. 1993; 268(30):22863-73. View

19.

Rybalkin S, Bornfeldt K, Sonnenburg W, Rybalkina I, KWAK K, Hanson K . Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 1997; 100(10):2611-21. PMC: 508463. DOI: 10.1172/JCI119805. View

20.

de Rooij J, Rehmann H, van Triest M, Cool R, Wittinghofer A, Bos J . Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. J Biol Chem. 2000; 275(27):20829-36. DOI: 10.1074/jbc.M001113200. View